SARAH KANTELIS: Open Payments
NPI 1881047892 · MISSION VIEJO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,807 in 212 payments from 19 companies in 2025. Trend: 2023 $6,118 · 2024 $2,971 · 2025 $8,807
Food & beverage: $5,057Speaker / faculty: $3,750
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $4,274 |
| Vanda Pharmaceuticals Inc. | 27 | $954 |
| Neurocrine BioSciences, Inc. | 17 | $509 |
| Otsuka America Pharmaceutical, Inc. | 22 | $440 |
| Teva Pharmaceuticals USA, Inc. | 19 | $410 |
| E.R. Squibb & Sons, L.L.C. | 14 | $393 |
| Janssen Pharmaceuticals, Inc | 11 | $374 |
| Alkermes, Inc. | 15 | $255 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $251 |
| Axsome Therapeutics, Inc. | 8 | $217 |
Products named: VRAYLAR, HETLIOZ, INGREZZA, COBENFY, REXULTI, AUSTEDO XR, SPRAVATO, ARISTADA.
Industry payments across CA — which companies pay providers there.
